Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2009

Roche Acquires Innovatis for $19.56M

  • Roche is taking over innovatis, a provider of automated cell analysis solutions, for €15 million, or $19.56 million. The firm focuses on cell counting, viability testing, and cell function analysis in research as well as bioproduction.

    The transaction is expected to be completed within the next few weeks. Innovatis will become a fully-integrated part of Roche Applied Science.

    "This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market,” says Jürgen Schwiezer, Ph.D., CEO of Roche Diagnostics. “Innovatis’ technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »